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Decidua basalis, the endometrium of pregnancy, is an important interface between maternal
and fetal tissues, made up of both maternal and fetal cells. Acute atherosis is a uteroplacental
spiral artery lesion. These patchy arterial wall lesions containing foam cells are predominantly
found in the decidua basalis, at the tips of the maternal arteries, where they feed into the
placental intervillous space. Acute atherosis is prevalent in preeclampsia and other obstetric
syndromes such as fetal growth restriction. Causal factors and effects of acute atherosis
remain uncertain. This is in part because decidua basalis is challenging to sample
systematically and in large amounts following delivery. We summarize our decidua basalis
vacuum suction method, which facilitates tissue-based studies of acute atherosis. We also
describe our evidence-based research definition of acute atherosis. Here, we
comprehensively review the existing literature on acute atherosis, its underlying
mechanisms and possible short- and long-term effects. We propose that multiple
pathways leading to decidual vascular inflammation may promote acute atherosis
formation, with or without poor spiral artery remodeling and/or preeclampsia. These include
maternal alloreactivity, ischemia-reperfusion injury, preexisting systemic inflammation, and
microbial infection. The concept of acute atherosis as an inflammatory lesion is not novel. The
lesions themselves have an inflammatory phenotype and resemble other arterial lesions of
more extensively studied etiology. We discuss findings of concurrently dysregulated proteins
involved in immune regulation and cardiovascular function in women with acute atherosis. We
also propose a novel hypothesis linking cellular fetal microchimerism, which is prevalent in
women with preeclampsia, with acute atherosis in pregnancy and future cardiovascular and
neurovascular disease. Finally, womenwith a history of preeclampsia have an increased risk of
premature cardiovascular disease. We review whether presence of acute atherosis may
identify women at especially high risk for premature cardiovascular disease.
Keywords: acute atherosis, inflammation, decidua basalis, preeclampsia, tolerance, cardiovascular disease,
placenta, microchimerismorg December 2021 | Volume 12 | Article 7916061
Pitz Jacobsen et al. Decidual Inflammation in Acute AtherosisINTRODUCTION
Arterial lesions specific to the spiral arteries at the fetal-maternal
border were first reported in 1945 (1). These lesions were later
termed acute atherosis, described as lipid-laden foam cells within
the intima, surrounded by fibrinoid necrosis and perivascular
immune cell infiltrate (2, 3). Acute atherosis is associated with
lower birthweight (4) and lower placental weight (5), and some
studies show that acute atherosis may be correlated with an
antiangiogenic profile (6, 7), all three of which are indicators of
placental dysfunction. Moreover, the well documented high
concomitance of acute atherosis and preeclampsia and other
obstetric syndromes suggests shared underlying mechanisms
(8–25).
Causal factors and effects of acute atherosis during pregnancy,
as well as the long-term effects on maternal cardiovascular
health, remain uncertain. There are several constraints on
studying the acute atherosis lesions histologically. Systematic
sampling of the decidua in large amounts following delivery is
quite difficult, and a uniform, evidence-based research definition
of acute atherosis lesions is historically lacking. As discussed
below, both issues have been addressed by us (22, 26). However,
even when these constraints are overcome, only a subset of the
decidua can realistically be evaluated in any morphological tissue
study, thus one can only with certainty determine the presence of
acute atherosis, and never the definitive absence.
Acute Atherosis Sampling Methodology
The ideal method for studying the impact of decidual acute
atherosis on placental function requires specimens of a
challenging nature; there are today only some very rare
hysterectomy specimens of severely preeclamptic women with
the placenta still in situ (27). In one such published case report,
acute atherosis of spiral arteries with severe narrowing of the
vascular lumen were associated with substantial infarcted areas
in the overlying parts of the placenta (28). Moreover, in this case
the lesions could be traced as deeply as the inner myometrium,
implying that the severity of the placental defects may be related
to the depth of the lesions. It is also noteworthy in this study that
remodeling of the placental bed spiral arteries, including the
myometrial segments, was absolutely normal in a few invaded
spiral arteries at the very center of the placental bed. This
suggests that non-invaded, more laterally situated vessels run a
higher risk of developing acute atherosis, again highlighting the
need for uniform sampling of relevant tissues for the study of
acute atherosis, preferably of the whole placental bed.
Several methods have been employed for sampling decidua
basalis for research purposes. These include placental bed
biopsies (29), biopsies from the basal plate of delivered
placentas (30), and our method of vacuum suctioning the
placental bed (31). Of these sampling methods, placental bed
punch or knife biopsy is the most invasive, but has the advantage
of providing myometrium, which is needed if the goal is to study
spiral artery remodeling or other features of this tissue (32).
Biopsies from delivered placentas is the least invasive sampling
method, and will yield moderate samples of decidua basalisFrontiers in Immunology | www.frontiersin.org 2tissue. However, if the goal is to study decidua basalis alone,
our vacuum suction technique is the superior method (32–34).
The vacuum suction technique is performed during caeserean
section, after delivery of the placenta, by applying vacuum
suction to the uterine wall. This method has the advantages of
an unbiased sampling and a large tissue yield. It is also time
efficient and without danger to maternal health (34). One
drawback is that tissue orientation is lost due to suctioning.
Still, the vacuum suction method provides tissue applicable for
acute atherosis research. We showed that higher rates of acute
atherosis detection was achieved using vacuum suction samples,
as compared to routinely sampled basal surface placental tissue
and fetal membrane roll biopsies from the same pregnancies
(33). The rate of decidual acute atherosis is thus likely
underestimated in most studies, and we recommend using the
vacuum suction technique if the goal is to study the lesions
independent of tissue orientation. Our large Oslo Pregnancy
Biobank, consisting of decidual tissue collected during elective
cesarean section, along with placental tissue biopsies, fetal
(umbilical artery as well as umbilical vein) and maternal blood
samples, amniotic fluid, and maternal muscle and fat tissue
biopsies, has enabled multiple studies comparing the presence
of decidual acute atherosis and dysregulated features of other
anatomical compartments (20–26, 31, 33, 35–41).
Nonuniformity in Acute Atherosis
Definitions
Historically, a uniform definition of acute atherosis has been
lacking. This may have led to discrepancies in reported rates of
acute atherosis across pregnancy groups. In addition, differences
in patient populations studied as well as in tissue collection and
evaluation methodology (e.g. antibody selection) may have
contributed. Moreover, clear definitions of perivascular
infiltrate (PVI) and fibrinoid necrosis have been lacking. We
set out to address these issues by attempting to establish an
evidence-based research definition of acute atherosis (22). After
examining 278 decidua basalis samples, we observed that
perivascular leukocyte infiltrates and increased fibrinoid did
not always correlate with adjacent foam cell lesions. Instead,
we concluded that these are features of the decidual pathology of
preeclampsia, while CD68+ foam cells are an essential aspect of
acute atherosis (Figure 1). Thus, we proposed that acute
atherosis should be diagnosed solely by the presence of foam
cell lesions, defined as two or more intramural, adjacent,
vacuolated CD68+ cells. Nonetheless, throughout this review,
we will include studies with other acute atherosis diagnosis
criteria as well.ACUTE ATHEROSIS ETIOLOGY
Hertig, who first described acute atherosis, proposed that vessel
damage followed by lipophage infiltration is what initiates acute
atherosis lesion development (1). Endothelial injury has long been
suspected as integral to decidual lesion development by others as
well (42). However, the lack of an association between acuteDecember 2021 | Volume 12 | Article 791606
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antihypertensive treatment, implies that hemodynamic forces
alone are not adequate for lesion development (43). Similar to the
heterogeneity of preeclampsia, acute atherosis is likely a
multifactorial pathology with several pathways leading to an
adverse uterovascular phenotype endpoint. We now have access
to 75 years of research into the nature of the histological lesions
known as acute atherosis, but have not finished elucidating the
complexity of its etiological andmechanistic molecular constituents.
One such potential constituent, however, may be endothelin-
1 (ET-1) (44). ET-1 is a highly potent vasoconstrictor (45). It is
upregulated by mechanical stretch (46) and hypoxia (47), and
plasma ET-1 is elevated in preeclampsia and gestational
hypertension (48, 49). It exerts its effects by binding G-proteinFrontiers in Immunology | www.frontiersin.org 3coupled receptors on vascular smooth muscle cells and
endothelial cells (50), a byproduct of which may be
intracellular lipid accumulation (51, 52). Thus, ET-1 may be a
common trigger for lipid accumulation within endothelial cells
in acute atherosis and in hepatocytes in the associated rare
disease, acute fatty liver of pregnancy (44).
Another vasoconstrictor of interest is angiotensin II, which
may play a role in the pathogenesis of atherosclerosis (53). We
have postulated a role in acute atherosis for activating antibodies
against the angiotensin II type 1 receptor (AA-AT1), after
demonstrating a clear association between AA-AT1 and
preeclampsia (54–56). Based on our cesarean delivery
population, we were unable to demonstrate any association
between AA-AT1 and acute atherosis (21). However, angiotensinFIGURE 1 | Staining of serial FFPE sections of decidua basalis tissue to identify spiral arteries. Slides are stained with (from left to right) Hematoxylin + Eosin (H + E),
desmin and Periodic acid–Schiff (PAS), cytokeratin 7 (CK7) and PAS, CD68 + PAS and Martius Scarlet Blue (MSB). Representative images of (A) spiral artery from a
normotensive control with complete physiological transformation, characterized by presence of CK7-positive trophoblasts and intramural fibrinoid (bright purple upon
PAS staining, white arrowhead) in the vessel wall, and complete absence of intramural smooth muscle cells (no desmin stain). (B) Spiral artery from a preeclampsia
patient with partial physiological transformation characterized by intramural fibrinoid, trophoblasts and areas with traces of mural smooth muscle cells (desmin-
positive). (C) Spiral artery with acute atherosis from same sample as in (B), lacking bright purple fibrinoid and CK7-positive trophoblasts in the vessel wall. Traces of
intramural smooth muscle cells (desmin positive) are seen. Fibrinoid necrosis is visible as a grey-pink material in the vessel wall (asterisk), which stains red upon MSB
staining (asterisk). Erythrocytes in the lumen of the AA artery stains red-brown upon MSB staining. Intramural CD68-positive foam cells are present (black
arrowhead). (D) Spiral artery from a preeclampsia patient with almost complete physiological transformation – evident by the lack of desmin-positive smooth muscle
cells and the presence of CK7-positive trophoblasts – yet acute atherosis lesion is present (asterisk; fibrinoid necrosis, black arrowhead; foam cells, white arrowhead;
purple physiological fibrinoid). Inset; higher power inset of foam cells. Reprinted from Fosheim et al. (35), with permission from the journal Placenta.December 2021 | Volume 12 | Article 791606
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both of these vasoconstrictor systems simultaneously would shed
more light on the possible involvement of G-protein cascades in
acute atherosis development.
The regulator of G protein signaling 2 (RGS2) likely has
implications for ET-1 and AA-AT1 signaling (58). Interestingly,
we have observed an association between acute atherosis and a
genotype associated with lower RGS2 expression (38). If G-
protein cascades indeed cause intracellular lipid accumulation,
as proposed by Coffey (44), we would expect early acute atherosis
lesions to contain lipid-laden endothelial or vascular muscle
cells. Accordingly, arterial lesions containing vacuolated
endothelial cells and myofibroblasts have been observed in
first-trimester curetted endometrium samples from therapeutic
and spontaneous abortions (59, 60). A higher incidence of such
lesions was observed in primigravida as compared to
multigravida (60). Primigravidity is associated with an
increased risk of preeclampsia (36, 61), often considered due to
excessive inflammation, although evidence is lacking (62).
Whether these lesions are precursors to full-blown acute
atherosis, and whether lipid accumulation within endothelial
cells and myofibroblasts is indeed the insult that catalyzes
intramural immune cell infiltration, remains to be investigated.
Acute atherosis shares morphological features with early
atherosclerotic lesions, which is recognized as an inflammatory
disease of the arterial walls (63). Both lesions present with
increased numbers of intimal macrophages, lipid-laden foam
cells, lipoprotein(a) throughout the vessel walls and extracellular
droplets of lipid as well as similar expression of intracellular
lipid-handling proteins (41, 64–67). Moreover, both acute
atherosis and atherosclerosis are associated with preeclampsia
and other states of systemic inflammation (68, 69).
However, there are several differences between acute atherosis
and atherosclerosis. Firstly, vessel caliber differs enormously.
Atherosclerosis is found in major arteries with a thick intimal
layer, and the vessels are supplied with oxygen and nutrients
from the vasa vasorum (70). Notably, the vasa vasorum may be
instrumental as a source of lipids in the development of
atherosclerosis (71–73). Spiral arteries are much smaller and
do not have an external blood supply. Preeclampsia is associated
with elevated lipid content in decidua basalis tissue, which may
act as a source of lipid compounds for lesion development (26).
Moreover, acute atherosis is not associated with plasma lipid
contents, further indicating a local rather than a systemic excess
of lipids (23). Secondly, research into the molecular composition
of acute atherosis versus atherosclerosis reveals several
dissimilarities. For instance, we have observed no LOX-1
positive endothelial cells or foam cells within the lesions of
spiral arteries (41), while this lipid scavenger receptor is a key
contributor to atherosclerotic development (74). Finally,
endothelial activation is important in atherosclerosis (75),
whereas evidence is conflicting with regards to endothelial
status in acute atherosis. Although one study reported
endothelial and interstitial extravillous trophoblast ICAM-1
expression in placentas with acute atherosis (76), we were
unable to detect any ICAM-1 expression within the acuteFrontiers in Immunology | www.frontiersin.org 4atherosis lesions (35). Moreover, the endothelial lining of the
artery wall is often destroyed in acute atherosis and there is
evidence of leakage of fibrin-like material from the circulation
into the vessel walls (35, 42, 77). Accordingly, in a study of
women with preeclampsia, we demonstrated elevated levels of
thrombomodulin – a marker of endothelial dysfunction (78) or
damage (79) – in those who had concomitant acute
atherosis (39).
Acute atherosis is not found outside of the uterus (80). The
lesions are focal and patchy, mainly localized downstream in the
circulation, at the tips of the decidua basalis spiral arteries.
The major remodeling problems occur upstream in the
myometrium (67, 80). Yet, there is a link between acute
atherosis formation and poor remodeling, as lesions are
commonly found downstream of inadequately remodeled
spiral arteries (77). The fully remodeled decidual segment of
the spiral artery may be considered as being somewhat “naked”
and is then likely more at risk for attacks both from the inside (by
luminal, circulating factors) as well as from the outside (by
components in the surrounding decidual tissue) in addition to
being especially exposed to ischemia-reperfusion injury due to
turbulent blood flow. Specifically, we postulate that these areas
are especially exposed to local inflammatory signaling molecules.
This may be compounded by their unique local environment
close to the semi-allogenic fetal cells and the resulting
inflammatory changes, potentially explaining why this
uteroplacental location seems to be a prerequisite for the
development of these particular atherosis lesions.
Inflammation does indeed appear to be clearly linked to acute
atherosis development. Spiral arteries affected by acute atherosis
contain huge deposits of IgM, as well as smaller amounts of IgG
and IgA within the arterial wall. In addition to immunoglobulins,
complement component 3 (C3) is often observed within acute
atherosis lesions (81–86). In addition, early immunohistochemistry
studies of the leukocyte infiltrate demonstrated T lymphocytes in
acute atherosis (87). We later expanded on these findings,
demonstrating increased concentrations of CD3+, CD8+ and
CD3+CD8- intramural T cells in the walls of spiral arteries with
acute atherosis compared to arteries from samples without acute
atherosis (37). Higher numbers of CD3+ and CD3+CD8- T cells
were also observed in the surrounding perivascular space.
Furthermore, a study by Gill and colleagues conducting flow
cytometry of basal plate samples demonstrated higher numbers
of M1-macrophages in acute atherosis, displaying a pro-
inflammatory phenotype (88). Fluorescence staining revealed
M1-macrophage localization within vessel walls of spiral arteries
affected by acute atherosis. Interestingly, a recent study from India
showed that the incidence of acute atherosis – after exclusion of
placental associated syndromes like fetal growth restriction,
pregnancy hypertension and diabetes – was significantly higher
in asymptomatic or mildly symptomatic SARS-CoV-2 positive
pregnant women as compared to SARS-CoV-2 negative pregnant
women (89). Finally, another support of acute atherosis
representing an inflammatory lesion is its resemblance to
systemic vasculitis, a general term applied to inflammation of
vessel walls that progresses to fibrinoid necrosis (90, 91).December 2021 | Volume 12 | Article 791606
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INFLAMMATION
We hypothesize that several mechanisms may trigger acute
atherosis. Our hypothesis places inflammation at the center of
lesion and as the final common pathway converged upon by
these different triggers (69). We believe these mechanisms mayFrontiers in Immunology | www.frontiersin.org 5act individually or in concert to produce acute atherosis, as
illustrated in Figure 2.
Maternal Alloreactivity
Human pregnancy is a dynamic balancing act for the maternal
immune system. The fetal allograft must peacefully coexist with
the maternal immune and cardiovascular systems, whilst theFIGURE 2 | Acute atherosis presence across the several forms of placental syndrome forms. Acute atherosis has been found in several forms of placental syndromes,
many of these associated with spiral artery remodeling deficiencies, including early-onset preeclampsia (PE) (illustrated on the left side of the Figure). This figure also
illustrates our concepts of how acute atherosis may be present also in late forms of preeclampsia (illustrated on the right side of the Figure), or indeed in any other
forms of placental dysfunction without spiral artery remodeling defects. Preplacentation factors impacts the early and ensuing placentation processes, and includes
both fetal-maternal tolerization processes as well as endometrial health (92). In this model, acute atherosis is seen as a consequence of any form of placental dysfunction
and its underlying mechanisms (69). The triggers include both the uteroplacental malperfusion pathway secondary to spiral artery remodeling problems (as in early-onset
preeclampsia) as well as the late-onset preeclampsia forms with other causes of placental malperfusion and syncytiotrophoblast stress (92, 93). Furthermore, this model
also proposes that acute atherosis itself may represent a risk factor for placental dysfunction and preeclampsia. This is in line with acute atherosis developing very
early in women with excessive vascular inflammation, such as in systemic lupus erythematosus, who also have a high risk for developing early-onset preeclampsia,
severe fetal growth restriction and intrauterine death, all severe clinical aspects of placental dysfunction. The line from the tolerization box to acute atherosis illustrate
how HLA-C/KIR interactions and alterations in level of immune-dampening molecules such as sHLA-G could contribute to lesion promotion at the maternal-fetal
interface, as discussed in this review. The maternal factors promoting the clinical forms of preeclampsia (e.g. early- and late-onset) as well as atherosis development
include cardiovascular, inflammatory and metabolic factors. Also, any form of clinical preeclampsia, with excessive circulation of proinflammatory factors and
hypertension may add to the risk for atherosis development, although hypertension in itself is not a mandatory requirement.December 2021 | Volume 12 | Article 791606
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microbial infections. Under any other circumstances, immune
cells would quickly target genetically foreign tissue. However, a
cascade of immune-modulating molecules acting throughout
pregnancy enable the conceptus to evade rejection until
parturition. The innate immune system is strengthened, while
adaptive immunity is weakened (94). Serial blood samples
collected at different time points during pregnancy have
revealed precise timing of particular immunological changes
(95). Aghaeepour and colleagues suggest deviations from this
“immune clock of human pregnancy” could indicate pregnancy-
related pathologies.
The fetus inherits half of its genetic material from the mother,
and the other half from the father. Given the extremely high
variability in major histocompatibility complex (MHC) genetics,
it is unlikely that the paternally inherited fetal MHC alleles are
identical to the maternally inherited fetal MHC alleles. Fetal
trophoblasts circumvent this obstacle and avoid rejection by local
maternal immune cells by not expressing most classical MHC
class I or class II surface molecules (96). They do, however,
express human leukocyte antigen (HLA) C and the non-classical
MHC molecules HLA-G, HLA-E and HLA-F (96–98). HLA-C
and HLA-G attenuate immune activation by binding to killer
immunoglobulin like receptors (KIR), which are abundantly
expressed on maternally derived immune cells (99, 100). KIR
activation prevents cytotoxicity by alloreactive T-cells (101), and
may induce apoptosis of activated T-cells and NK cells (102,
103). Invading extravillous trophoblasts rely on these KIR/HLA-
interactions to avoid immune cell attacks. In fact, there is a
positive correlation between the amount of surface HLA-G
expression and the depth of trophoblast invasion into the
decidua (104).
Several factors may influence these tolerogenic pathways. As
HLA-C is the only polymorphic histocompatibility antigen
expressed by fetal cells at the fetal-maternal interface, paternal
HLA-C genotype is particularly important. In fact, HLA-C
mismatched pregnancies are characterized by a higher
percentage of activated maternal T-cells (105). Moreover, the
combination of fetal HLA-C and maternal killer immunoglobulin
like receptor (KIR) genotypes may greatly predispose
pregnancies to preeclampsia (106). We have expanded on this
finding by showing that the combination of fetal HLA-C2 with
the maternal KIR-B haplotype was significantly associated with
acute atherosis in preeclampsia (25).
Similarly, inadequate induction of tolerance by HLA-G is
detrimental to pregnancy health (107). Membrane bound HLA-
G expression is lower on trophoblasts from preeclamptic
placentas (108, 109). Circulating soluble HLA-G (sHLA-G) is
also lower in preeclampsia throughout all trimesters, compared
to pregnancies that remain normotensive (110). We have shown
that maternal sHLA-G inversely correlates with the level of
placental dysfunction, the latter evaluated by maternal levels of
the antiangiogenic factor sFlt-1, or by the sFlt-1/PlGF ratio (36),
and that fetal polymorphisms in the 3’UTR region of HLA-G are
associated with presence of acute atherosis in preeclampsia (24).
Our hypothesis is that these polymorphisms lead to altered HLA-Frontiers in Immunology | www.frontiersin.org 6G expression in the decidua basalis, affecting local fetal-maternal
immune tolerance and in turn promoting development of acute
atherosis. Failure to establish fetal-maternal tolerance may also
influence trophoblast invasion into the decidua. These
extravillous trophoblasts are involved in the plugging and
remodeling of uteroplacental spiral arteries in early
pregnancy (80).
Ischemia-Reperfusion Injury
The first 10 weeks of pregnancy, the spiral arteries extending
from the placenta to the endometrial surface of the decidua are
effectively plugged, and the fetus exists in a state of physiological
hypoxia (111, 112). At the end of the first trimester, the maternal
vessels of the decidua open up and the placenta is submerged in
maternal blood (111). This marks a dramatic shift in the
fetoplacental exposure to the maternal cardiovascular and system.
Throughout pregnancy, uteroplacental blood flow increases,
reaching up to 750 ml/minute at term, about 25% of maternal
cardiac output (113). At the same time, the approximate 5-fold
increase in diameter of the terminal coils of fully remodeled spiral
arteries dramatically slows down the speed of the blood entering
the intervillous space (111). Failure of proper spiral artery
remodeling results in downstream placental malperfusion. The
retention of smooth muscle within the arterial wall likely causes
ischemia-reperfusion injury (114), and not impaired flow volume
nor uteroplacental hypoperfusion. In addition, we argue that
placental malperfusion may not be exclusively secondary to
failure of spiral artery remodeling. Failed remodeling may be
considered an “external” cause of placental malperfusion and is
typically seen in early-onset preeclampsia. Late-onset preeclampsia
affects a greater rate of women than the early-onset form, and spiral
artery remodeling is rarely affected. In this setting, malperfusion
may be caused by two “internal” pathways. In the one pathway,
placental senescence causes a syncytiotrophoblast stress response as
the pregnancy progresses towards term and thereafter. The other
pathway occurs with particularly large placentas, such as in
multiple gestations, in which compression leads to placental
congestion and thereby malperfusion (93, 115). The ensuing
disturbances in calcium-homeostasis may cause endoplasmic
reticulum stress and initiate the unfolded protein response,
ultimately leading to cell death (116, 117). Moreover, intracellular
buildup of reactive oxygen species induces upregulation and
secretion of the proinflammatory cytokines TNF and IL-1b (118,
119). ER stress and oxidative stress in placental tissues are both
features of preeclampsia (31, 117, 120), and may also play a role in
the strongly associated acute atherosis lesion development.
High pressure and turbulent blood flow may also damage the
endothelial lining of the terminal coils of spiral arteries, as well as
syncytiotrophoblasts coating placental villi. Analysis of
hemodynamic forces on vascular endothelial cells has shown
that disturbed blood flow and continuous low grade shear stress
acting on the arterial wall may promote atherogenesis (121). This
is in line with the increased incidence of atherosclerotic lesions at
arterial branch points or sections with high curvature (122, 123).
Endothelial cells possess surface molecules capable of detecting
shear stress and inducing gene transcription through the Ras-December 2021 | Volume 12 | Article 791606
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gene expression is a transient upregulation of the monocyte
chemotactic protein 1 (MCP-1) (125). Overexpression of MCP-1
attracts macrophages and may induce infiltration into vessel
walls (126). Interestingly, endothelial MCP-1 is upregulated in
preeclampsia (127, 128), possibly due to atherogenic blood flow,
and could possibly be involved in CD68+ cell recruitment to the
sites of lesion development (129, 130).
Ferroptosis is a recently discovered mode of iron-dependent
cell death (131, 132). Lipoxygenases and other enzymes may
induce ferroptosis in a controlled manner (133). In addition, and
more relevant to the topic at hand, ferroptosis may occur due to
iron dysregulation and free-radical chain reactions, leading to
hydroxyl and peroxyl radicals (133). Recently, ferroptosis has
gained attention as a possible target against ischemia-reperfusion
injury (134–136). Thus, ferroptosis may play a role in early-onset
preeclampsia following incomplete spiral artery remodeling.
Interestingly, huge amounts of iron have been observed in
atherosclerotic lesions (137), and lipid peroxidation is known
to play a significant role in atherogenesis (138). Moreover,
animal experiments have shown alleviation of atherosclerosis
through inhibition of ferroptosis (139). However, the role of
iron-dependent cell death due to ischemia-reperfusion in acute
atherosis development remains to be investigated.
Preexisting Systemic Inflammation
Systemic inflammation is associated with many chronic diseases,
such as obesity, diabetes mellitus and cardiovascular disease, as
reviewed in (140–142). Considering that even normal pregnancy
is associated with elevated systemic inflammation (143), one
would expect heightened baseline inflammation to be associated
with higher rates of obstetric complications linked to the
maternal immune system. This is indeed what is observed.
Obesity, diabetes mellitus and high blood pressure are all
substantial risk factors for miscarriage (144–146), preeclampsia
(92, 147) and fetal neurodevelopmental disorders (148–150). In
line with the effects of other chronic inflammatory conditions on
pregnancy, pregnant women with autoimmune disease
experience higher rates of hypertensive disorders of pregnancy,
intrauterine growth restriction, preterm delivery and autism
spectrum disorder in their offspring (151–154). Interestingly,
autoimmune disorders are also commonly observed in
association with acute atherosis (155, 156). In fact, lesions have
been observed as early as the first trimester in women with
systemic lupus erythematosus (157).
Microbial Infection
Many tissues first thought to be sterile have been shown to
harbor dormant bacteria. This includes blood (158, 159), seminal
fluid (160) and possibly the placenta (161) – although this latter
claim is disputed (162). The source of these bacteria may be the
gut (163), the oral cavity (164) or the urinary tract (165). The
iron dysregulation and dormant microbes hypothesis proposes
these bacteria may be resuscitated from dormancy by free iron
and manifest a diverse range of chronic inflammatory diseases
previously thought to not possess infectious properties such as
preeclampsia and atherosclerotic disease (166). Viable bacteriaFrontiers in Immunology | www.frontiersin.org 7release lipopolysaccharide (LPS) or lipoteichoic acid (LTA). This
initiates a cascade of immune responses, including a dramatic
upregulation of many circulating cytokines and other acute
phase signaling molecules like serum amyloid A1 (SAA1) and
C-reactive protein (167, 168). As extensively reviewed by Kell
and Kenny, there are several lines of evidence pointing towards
microbial contribution in the development of preeclampsia
(169). There is high co-occurrence between bacterial infections
and preeclampsia. Examples include Chlamydia pneumoniae
(170, 171) and Helicobacter pylori (172). Several biomarkers
associated with preeclampsia have also been linked to
microbial infections, including sFlt-1/PlGF ratio (173, 174) and
SAA1 (167). In support of the concept that preeclampsia
development has a microbial component, is the virtual absence
of preeclampsia in pregnancies with Toxoplasma gondii infection
treated with anti-microbial medication (spiramycin) (175). Kell
and others have also argued for the existence of a microbial
component in atherosclerosis with quite compelling evidence
(159, 166, 176). Patients with chronic bacterial infections are
substantially more at risk for atherosclerosis (177, 178), and LPS
is regularly used to generate animal models of the disease (179,
180). Moreover, atherosclerotic plaques contain bacterial DNA
(181, 182) and elevated levels of iron (180), adding credence to
the iron dysregulation and dormant microbes hypothesis. The
similarities to atherosclerosis have led others to speculate that an
infectious trigger underlies the development of acute atherosis as
well (183, 184). However, this matter remains unsettled.A NEW HYPOTHESIS LINKING CELLULAR
FETAL MICROCHIMERISM WITH ACUTE
ATHEROSIS IN PREGNANCY AND
FUTURE CARDIOVASCULAR AND
NEUROVASCULAR DISEASE
Cellular fetal microchimerism (cFMC) arises when cells of fetal
origin are transferred to maternal blood and tissues during
pregnancy (185). These cells are known to possess stem cell-
like properties, capable of differentiating into endothelial cells,
smooth muscle cells and even leukocytes (186, 187). During
pregnancy, a lot of fetal material leaks into maternal circulation.
While cell free fetal DNA and other debris is rapidly cleared
following delivery (188) and likely completely absent from
maternal systems postpartum, cFMC may persist for decades.
In fact, fetal cells have been observed in maternal circulation up
to 27 years postpartum, indicating that these cells may inhabit
maternal systems throughout life (189). Restorative as well as
detrimental effects have been attributed to cFMC, possibly tied to
fetal-maternal histocompatibility (185). Of particular interest in
the context of this review is the apparent detrimental effect of
cFMC on autoimmunity (190, 191). The trigger has been
proposed to be a maternal alloimmune response towards fetal
cells expressing foreign HLA surface peptides (191). By far the
majority of patients diagnosed with autoimmune disorders are
women (192), which could partly be due to the acquisition of
fetal cells during pregnancy.December 2021 | Volume 12 | Article 791606
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microchimeric cells are more prevalent in pregnancies
complicated by preeclampsia (193, 194) or severe fetal growth
restriction combined with impaired placental perfusion (195).
If this is due to increased cell transfer, reduced clearance or
reduced migration from maternal blood into maternal tissues is
unclear (185, 196). We hypothesize that when the placenta is
dysfunctional, fetal cells leak more freely across into maternal
blood and subsequently other tissues. These cells may then inhabit
maternal vessels, in the presence or absence of endothelial
damage, and induce a maternal anti-fetal immune response
towards the vascular endothelium. This could explain the
association between male cFMC and an increased cardiovascular
mortality hazard ratio (197). However, this last observation was
based on a total of only 5 cardiovascular deaths. A recent study on
a much larger cohort found that male-origin microchimerism was
associated with reduced risk of ischemic heart disease as well as no
association between microchimerism and ischemic stroke (198).
Microchimerism is not unique to pregnancy. Low levels of
donor cells may be acquired following solid organ transplantation
(199). The presence of such microchimerism has been linked to
graft acceptance (200) as well as graft rejection (201). As with
autoimmune diseases and cFMC, the effect of donor
microchimerism may depend on how well the host tolerates the
graft. Interestingly, vascular lesions have been observed in arteries
surrounding transplanted organs following kidney transplant
rejection (202), after liver transplantation (203) and after heart
transplantation (204). These lesions are characterized by large
amounts of lipids, IgM and C3 (205), and thus bear striking
resemblance to acute atherosis.
Our novel hypothesis states that placental dysfunction leads to
augmented cFMC. If persistent in the circulation or alternatively
engrafted in maternal endothelium, these semi-allogenic cells could
cause further inflammation, particularly in vessel walls, and initiate
development of inflammatory arterial lesions such as acute
atherosis. As cFMC persist decades after pregnancy, there may be
a role for these cells in the pathogenesis of chronic cardiovascular
and neurovascular disease in the long term as well. We believe this
hypothesis merits further testing in translational clinical studies.CLINICAL TRANSLATION
During Pregnancy
Acute atherosis is associated with arterial thrombosis, placental
infarction and perinatal death (22, 28, 30, 206, 207). This has led
researchers to propose aspirin as a possible treatment for acute
atherosis (208). Aspirin is an effective prophylactic treatment
against thrombosis (209). Outside of pregnancy, aspirin is
widely used for primary and secondary prevention of
atherosclerotic CVD (210). Daily low-dose aspirin started during
the first trimester has shown a substantially reduced risk of
preeclampsia in women at high risk (211–213). Whether this
effect is related to a reduced tendency of blood clot formation, and
how this may relate to acute atherosis, remains to be investigated.
Acute atherosis lesions may also effectively reduce the
diameter of uteroplacental spiral arteries, causing aberrantFrontiers in Immunology | www.frontiersin.org 8blood flow (69, 111). The evidence of this latter claim is,
however, conflicting. Supporting this, an early study of only 6
cases showed a trend between acute atherosis and high uterine
artery pulsatility index, which could reflect obstructed spiral
artery blood flow (214). Furthermore, another research group
showed that acute atherosis is associated with a higher incidence
of placental lesions characteristic of maternal vascular
hypoperfusion (215). Placental lesions are also associated with
abnormal uterine velocimetry measurements among women
with intrauterine fetal growth restriction (216). In contrast to
these findings, one study found no association between uterine
artery pulsatility index and acute atherosis (217). The reasons for
these discrepant findings may be that the spiral arteries are not
visualized directly by Doppler studies, but rather indirectly by
studying the blood flow of the larger uterine arteries (214, 216–
218). Uterine and spiral arteries differ much in structure, size and
function. Uterine artery ultrasonography has historically been
viewed as a reflection of spiral artery remodeling (219), but
recent studies indicate that the radial arteries, as well as the
maternal vascular system, may have a larger impact on uterine
artery waveforms than the spiral arteries (218). Doppler
ultrasonography is hence unlikely a reliable tool for diagnosing
uteroplacental acute atherosis.
Postpartum: Targeting the Women at
Highest Risk of Premature Cardiovascular
Disease?
We have put forth the hypothesis that women with concomitant
preeclampsia and acute atherosis are at especially high risk for
developing atherosclerosis and premature cardiovascular disease
(130). If pregnancy is a physiological stress test (220, 221), then
preeclampsia is an unmasking of compromised maternal
cardiovascular health. Time and time again preeclampsia has
been linked to future maternal cardiovascular disease in one
form or another (222–230). The severity of preeclampsia also
correlates with ischemic heart disease incidence rate (231).
Moreover, fetal manifestations of placental dysfunction, such
as intrauterine growth restriction, further add to maternal risk of
cardiovascular disease (232). Abnormal placentation also
associates with infertility or subfertility, both of which are
associated with poor long-term cardiovascular health (233,
234). As described above, acute atherosis may disturb placental
perfusion (69, 111), and is associated with low birth weight (4)
and low placental weight (5). Acute atherosis may thus play a
role in producing and/or exacerbating maternal and fetal
symptoms of placental dysfunction, associated with high
cardiovascular disease risk.
There are striking similarities between acute atherosis and
atherosclerosis, indicative of shared pathophysiology. We know
that preeclampsia is associated with a substantial atherosclerotic
load (235). Compared to normotensive women and women with
gestational hypertension, women with preeclampsia have higher
carotid intima-media thickness (CIMT) (236, 237) – increasingly
used as a surrogate marker for preclinical atherosclerosis (238).
In some studies, these differences remained evident up to 18
months postpartum (236, 237). However, other studies with
longer follow-up did not corroborate these findings (239, 240).December 2021 | Volume 12 | Article 791606
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postpartum in women with preeclampsia compared to controls
(241). Instead, they found increased intima thickness as well as
intima-media ratio in cases versus control. The authors suggest
that these measures are preferable to the conventional CIMT for
assessing cardiovascular disease risk in women with a history of
preeclampsia. As lesions of the placental bed manifest during a
shorter time span compared to atherosclerosis (possibly due to
the proximity to the foreign fetus and the excessive inflammation
of pregnancy), acute atherosis may possibly be used as an
indicator of women with excessive atherosclerotic load (130).
Several studies have examined the link between decidual
lesions and subsequent cardiovascular health. Two retrospective
cohort studies by the same research group have revealed long-term
cardiovascular consequences of decidual vasculopathy (242, 243).
Decidual vasculopathy was in these studies defined by vascular
fibrinoid necrosis and lipid-filled foam cells in the vascular wall,
thus sharing some of the features traditionally used for acute
atherosis (244). The first study examined cardiovascular
parameters 2-74 months postpartum in women whose index
pregnancies were complicated by preeclampsia. Women with
concomitant decidual vasculopathy and preeclampsia had higher
diastolic blood pressure, lower left ventricular stroke volume and
higher total peripheral vascular resistance as compared to women
with only preeclampsia (243). Decidual vasculopathy did,
however, not correlate with circulating lipids or thrombophilia
postpartum. The second study demonstrated a higher prevalence
of chronic hypertension several years postpartum in women who
had concomitant decidual vasculopathy and preeclampsia,
compared to women who only had preeclampsia. These results
remained significant after correcting for chronic hypertension
before index pregnancy (242).
A small study comprising only 3 cases of acute atherosis
showed higher levels of triglycerides and low-density lipoprotein
in these women on the first day postpartum as compared to
women without acute atherosis (245). Our group conducted a
larger study where we also measured triglycerides and
cholesterols (among other circulating biomarkers) the day of
cesarean section. We observed no differences in circulating
cardiovascular biomarkers between women with acute
atherosis and women without. However, when restricting the
analyses to women of advanced maternal age (age 36-44) we
observed significantly elevated low-density lipoprotein and ApoB
in women with acute atherosis (20). These studies highlight the
potential use of acute atherosis in targeting women at
particularly high risk of cardiovascular disease – a concept
promoted by us and others previously (246, 247). Utilizing the
more readily detected maternal vascular malperfusion lesions of
the placenta has also been suggested (248), although some claimFrontiers in Immunology | www.frontiersin.org 9cardiovascular disease risk should be linked with atherosclerotic
lesions of the uteroplacental artery instead of decidual basal
artery or placental lesions (249).FUTURE RESEARCH OPPORTUNITIES
As outlined above, there is substantial evidence backing up the
concept of acute atherosis as a pregnancy-specific inflammatory
arterial lesion. However, many uncertainties regarding acute
atherosis remain. Firstly, the risk factors and triggers that
initiate lesion development have not been fully elucidated,
though there seems to be a consensus among researchers that
endothelial damage is part of it. Damage could stem from
ischemia-reperfusion injury, infections or excessive activation
of G-protein cascades, to name a few. Further research into the
molecular constituents of acute atherosis – in particular early
lesion stages – could shed some light on this issue. Secondly,
there are many candidates for drivers of inflammation and lesion
development following endothelial insult. Further knowledge of
which pathways play a substantial role could guide the
development of prophylactic treatments of obstetric syndromes
tightly associated with acute atherosis. This includes our
suggestion of testing whether the use of anti-atherogenic
statins during severe preeclampsia or fetal growth restriction,
such as in women with systemic lupus, may ameliorate acute
atherosis, improve uteroplacental perfusion and enhance
pregnancy outcome (69). Thirdly, the long-lasting implications
of pregnancy affected by acute atherosis on maternal health need
further research. There is a clear lack of studies with hard
endpoints to show if acute atherosis, as we have proposed, can
be used to identify women at substantial risk for premature
cardiovascular disease and death.AUTHOR CONTRIBUTIONS
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